Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | GLA | P06280 | 1/20 | 0.69 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | NPY1R | P25929 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | NPY2R | P49146 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8709002 | 1.00 | SLC29A1 (0.69) | SLC29A1LMNAALDH1A1GLAPMP22 | |
| SCHEMBL14929512 | 0.91 | ADORA3 (0.72) | SLC29A1LMNAALDH1A1GLAPMP22 | |
| SCHEMBL40635 | 0.91 | ADORA3 (0.72) | SLC29A1LMNAALDH1A1GLAPMP22 | |
| SCHEMBL17234118 | 0.91 | ADORA3 (0.72) | SLC29A1LMNAALDH1A1GLAPMP22 | |
| SCHEMBL8425718 | 0.91 | ADORA3 (0.72) | SLC29A1LMNAALDH1A1GLAPMP22 | |
| SCHEMBL23647923 | 0.91 | ADORA3 (0.72) | SLC29A1LMNAALDH1A1GLAPMP22 | |
| SCHEMBL40634 | 0.91 | ADORA3 (0.72) | SLC29A1LMNAALDH1A1GLAPMP22 | |
| SCHEMBL3164693 | 0.91 | ADORA3 (0.72) | SLC29A1LMNAALDH1A1GLAPMP22 | |
| SCHEMBL20801120 | 0.91 | ADORA3 (0.72) | SLC29A1LMNAALDH1A1GLAPMP22 | |
| SCHEMBL14946390 | 0.91 | ADORA3 (0.72) | SLC29A1LMNAALDH1A1GLAPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1998016539-A1 | NOVEL THERAPEUTICALLY ACTIVE ADENOSINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1998-04-23 | — | — | WO | disclosed |
| WO-1997033590-A1 | A METHOD OF TREATING DISORDERS RELATED TO CYTOKINES IN MAMMALS | NOVO NORDISK A/S (DK) | 1997-09-18 | — | — | WO | disclosed |
| WO-1997033591-A1 | A METHOD OF TREATING DISORDERS RELATED TO CYTOKINES IN MAMMALS | NOVO NORDISK A/S (DK) | 1997-09-18 | — | — | WO | disclosed |
| US-5589467-A | TREATING CENTRAL NERVOUS SYSTEM DISORDERS | NOVO NORDISK A/S (DK) | 1996-12-31 | — | — | US | disclosed |
| US-5578582-A | Methods of treating ischemia with C2, N6 -disubstituted adenosine derivatives | NOVO NORDISK A/S (DK) | 1996-11-26 | — | — | US | disclosed |
| EP-0719275-A1 | CHEMICAL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1996-07-03 | — | — | EP | disclosed |
| US-5432164-A | Anticonvulsants | NOVO NORDISK A/S (DK) | 1995-07-11 | — | — | US | disclosed |
| US-5430027-A | 2-chloro-N6 -substituted adenosines, their pharmaceutical compositions, and activity in treating ischemias | NOVO NORDISK A/S (DK) | 1995-07-04 | — | — | US | disclosed |
| WO-1995007921-A1 | CHEMICAL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1995-03-23 | — | — | WO | disclosed |
| EP-0609375-A1 | NOVEL 2,6-DISUBSTITUTED PURINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1994-08-10 | — | — | EP | disclosed |
| EP-0607367-A1 | NOVEL ADENOSINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1994-07-27 | — | — | EP | disclosed |
| WO-1993023417-A1 | NOVEL ADENOSINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1993-11-25 | — | — | WO | disclosed |
| WO-1993008206-A1 | NOVEL 2,6-DISUBSTITUTED PURINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1993-04-29 | — | — | WO | disclosed |